📄 medicine

Genetically predicted 3-hydroxybutyrate and the risk of non-alcoholic fatty liver disease: a Mendelian randomization study

This Mendelian randomization study provides genetic evidence that higher circulating levels of 3-hydroxybutyrate are causally associated with a reduced risk of non-alcoholic fatty liver disease, whereas acetoacetate and acetone show no significant causal link.

Original authors: Jiawei Wang, Yongxin Ma, Xin Ma, Bendong Chen, Yang Bu

Published 2026-06-30

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Jiawei Wang, Yongxin Ma, Xin Ma, Bendong Chen, Yang Bu

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A Genetic Detective Story

Imagine you are trying to figure out if eating a specific type of food (like a ketogenic diet) actually causes your liver to get healthier, or if it just happens to be that way because of other lifestyle factors. It's like trying to tell if a rooster crowing causes the sun to rise, or if they just happen to happen at the same time.

This study, conducted by researchers from Ningxia Medical University, used a clever genetic detective technique called Mendelian Randomization (MR) to solve this mystery. Instead of asking people what they eat (which can be unreliable), they looked at people's DNA.

Think of your genes as a lottery ticket you get at birth. Nature randomly deals these cards out. If you are born with a genetic "ticket" that naturally keeps your levels of a specific chemical high, you are essentially a "natural experiment" group. By comparing people with these "high chemical" tickets to those with "low chemical" tickets, the researchers could see if the chemical itself causes changes in liver health, without the noise of diet, exercise, or weight interfering.

The Characters: The Three Ketone Brothers

The study focused on three specific chemicals produced by the liver when it burns fat for fuel. These are called ketone bodies. You can think of them as three brothers working in the same factory:

3-Hydroxybutyrate (3-HB): The "Star Player."
Acetoacetate: The "Middle Brother."
Acetone: The "Youngest Brother."

The researchers wanted to know: Do these brothers help fix a "clogged" liver (known as Non-Alcoholic Fatty Liver Disease, or NAFLD), or do they make it worse?

The Investigation: What the DNA Said

The researchers used a massive database of genetic information from over 370,000 people of European ancestry. They looked for the genetic "tickets" that determine how much of each ketone body a person naturally produces.

The Findings:

The Star Player (3-Hydroxybutyrate): The study found a clear link. People who genetically produced more 3-Hydroxybutyrate had a significantly lower risk of developing fatty liver disease.
- The Analogy: Imagine 3-Hydroxybutyrate is a specialized janitor. The more janitors you have in the liver factory, the cleaner the building stays, and the less likely it is to get clogged with fat. The study suggests that having a genetic tendency to produce more of this "janitor" protects the liver.
The Other Brothers (Acetoacetate and Acetone): The study found no significant link between these two and the risk of fatty liver.
- The Analogy: Even though Acetoacetate and Acetone work in the same factory, having more of them didn't seem to change whether the building got clogged or not. They weren't the "hero" in this specific story.

The "Reverse" Check

To make sure they weren't getting the cause and effect mixed up (e.g., maybe a healthy liver just happens to produce more 3-Hydroxybutyrate?), they ran the test backward. They asked: "Does having a fatty liver cause your body to produce less 3-Hydroxybutyrate?"

The Result: No. The study found that having a fatty liver did not genetically change the levels of these ketone bodies. This confirmed that the relationship goes one way: Higher 3-Hydroxybutyrate $\rightarrow$ Lower Liver Risk.

The "Group Chat" Test (Multivariable MR)

The researchers also asked a tricky question: "If all three brothers are in the room together, is 3-Hydroxybutyrate still the one doing the work, or is it just the group?"

They ran a special analysis where they looked at all three at once. The result? 3-Hydroxybutyrate still stood out. Even when accounting for the other two brothers, 3-Hydroxybutyrate remained the one associated with a healthier liver. This suggests it's not just a general "ketone effect," but something specific to this one molecule.

What the Study Does Not Say

It is very important to stick to what the paper actually claims:

It does not prove that eating a Keto diet will cure fatty liver. The study looked at genetics, not diet. Just because your genes make you good at producing this chemical doesn't mean you can eat a specific diet to force your body to do the same thing.
It does not recommend taking supplements. The paper explicitly states these findings should not be taken as proof that taking extra 3-Hydroxybutyrate supplements will prevent or treat the disease.
It is not a final medical verdict. The authors emphasize that while the genetic evidence is strong, we still need real-world experiments and clinical trials to understand how it works and if we can use this knowledge to treat patients.

The Bottom Line

This study used a genetic "lottery" to show that people who naturally have higher levels of 3-Hydroxybutyrate are less likely to develop fatty liver disease. It suggests this specific chemical might be a protective "janitor" for the liver. However, the study stops short of telling us how to use this information in the clinic; it simply provides a strong clue for scientists to investigate further.

Technical Summary: Genetically Predicted 3-Hydroxybutyrate and the Risk of Non-Alcoholic Fatty Liver Disease

Problem Statement
Non-alcoholic fatty liver disease (NAFLD) is a prevalent systemic metabolic disorder characterized by hepatic steatosis, ranging from simple fatty liver to steatohepatitis, fibrosis, and cirrhosis. While observational and experimental studies suggest that ketogenic interventions and ketone bodies (specifically 3-hydroxybutyrate) may reduce hepatic fat accumulation and improve metabolic parameters, the causal nature of this relationship remains unclear. Existing literature is often confounded by lifestyle factors, reverse causality, and the complexity of ketogenic diets, which involve multiple simultaneous metabolic changes (e.g., weight loss, insulin reduction, altered lipid metabolism). Consequently, it is difficult to determine if 3-hydroxybutyrate itself plays a direct causal role in modulating NAFLD risk.

Methodology
This study employed a two-sample Mendelian randomization (MR) design to investigate the causal associations between three ketone bodies—3-hydroxybutyrate, acetoacetate, and acetone—and NAFLD.

Data Sources: Summary-level genome-wide association study (GWAS) data for the ketone bodies were derived from the UK Biobank (Nightingale Health platform, 2020), and NAFLD GWAS data were obtained from the IEU OpenGWAS database (Fairfield et al., 2021). All datasets comprised participants of European ancestry.
Instrumental Variables (IVs): Single nucleotide polymorphisms (SNPs) associated with each ketone body at genome-wide significance ( $P < 5 \times 10^{-8}$ ) were selected. Linkage disequilibrium clumping ( $r^2 < 0.001$ ) and F-statistic filtering ( $F > 10$ ) were applied to ensure instrument strength and independence.
Analytical Approach:
- Primary Analysis: Inverse-variance weighted (IVW) method.
- Complementary Analyses: MR-Egger, weighted median, simple mode, and weighted mode methods were used to validate robustness.
- Reverse MR: Conducted to test if genetic liability to NAFLD causally influences circulating ketone body levels.
- Multivariable MR (MVMR): Performed to assess whether the association of 3-hydroxybutyrate with NAFLD is independent of the other two ketone bodies.
- Sensitivity Analyses: Included heterogeneity assessment (Cochran's Q), pleiotropy testing (MR-Egger intercept, MR-PRESSO), and leave-one-out analysis to rule out the influence of single outlier SNPs.

Key Results

Forward MR: Genetically predicted higher levels of 3-hydroxybutyrate were significantly associated with a reduced risk of NAFLD. The primary IVW analysis yielded an odds ratio (OR) of 0.448 (95% CI 0.249–0.805, $P = 0.007$ ). The weighted median method supported this inverse association, while other methods showed directionally consistent but non-significant estimates.
Other Ketone Bodies: Genetically predicted acetoacetate (IVW OR = 0.677, $P = 0.326$ ) and acetone (IVW OR = 0.839, $P = 0.408$ ) showed no statistically significant association with NAFLD risk.
Reverse MR: No evidence was found that genetic liability to NAFLD causally affects circulating levels of 3-hydroxybutyrate, acetoacetate, or acetone, suggesting the forward association is not driven by reverse causality.
Multivariable MR: When all three ketone bodies were included in a single model, 3-hydroxybutyrate remained significantly associated with a reduced NAFLD risk (OR = 0.407, 95% CI 0.200–0.829, $P = 0.013$ ), whereas acetoacetate and acetone remained non-significant.
Sensitivity: Leave-one-out analysis confirmed that the results were not driven by any single SNP. No significant heterogeneity or horizontal pleiotropy was detected.

Significance and Claims
The authors claim this study provides the first genetic evidence using Mendelian randomization to suggest a causal link where higher genetically predicted 3-hydroxybutyrate levels are associated with a lower risk of NAFLD. The study highlights the specificity of this effect to 3-hydroxybutyrate, as the other major ketone bodies (acetoacetate and acetone) did not show similar associations.

However, the paper maintains a modest tone regarding clinical implications. The authors explicitly state that these findings should not be interpreted as direct evidence that ketogenic diets or exogenous ketone supplementation can prevent or treat NAFLD. They emphasize that while the genetic data supports a causal role for 3-hydroxybutyrate, further experimental studies, prospective cohorts, and randomized clinical trials are necessary to validate the biological mechanisms and determine the clinical utility of modulating 3-hydroxybutyrate levels for NAFLD management. The study concludes that while it offers a genetic epidemiological foundation, the translation to therapeutic strategies requires further investigation.